Cardium Therapeutics, Inc. Form 8-K January 26, 2011

# **UNITED STATES**

## **SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

# FORM 8-K

## **CURRENT REPORT**

pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

DATE OF REPORT (Date of earliest event reported): January 24, 2011

001-33635

(Commission file number)

# **CARDIUM THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

Edgar Filing: Cardium Therapeutics, Inc. - Form 8-K

Delaware (State of incorporation) 27-0075787 (IRS Employer Identification No.)

12255 El Camino Real, Suite 250

San Diego, California 92130 (Address of principal executive offices) (858) 436-1000 (Registrant s telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### ITEM 8.01 OTHER EVENTS.

On January 24, 2011, Cardium Therapeutics, Inc. (Cardium) issued a press release reporting that its exchange listing compliance plan submitted on December 2, 2010 has been accepted by the NYSE Amex LLC. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

## ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

99.1 Press Release of Cardium issued on January 24, 2011.

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### CARDIUM THERAPEUTICS, INC.

Date: January 26, 2011

By: /s/ Christopher J. Reinhard Christopher J. Reinhard Chief Executive Officer